The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma

Collier, N.J.; Ali, Faisal; Lear, John T.

doi:10.1080/14737140.2016.1230020

Cited by 10 publications

(8 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correct management of side effects could improve patients' health-related quality of life, thus reducing treatment discontinuation. Experiencing regimen adjustment with potential treatment holiday as well as novel approaches for side profile management might provide options for improving the tolerability of this therapy [49][50][51]. Moreover, positive results from trials conducted in patients with Gorlin syndrome showed the possibility of using this HPI not only for treatment of one laBCC but also for cancer chemoprevention.…”

Section: Perspectives and Conclusionmentioning

confidence: 99%

Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma

Villani

Fabbrocini

Costa

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Hedgehog inhibitors are promising alternative treatments for patients with advanced basal cell carcinomas. Sonidegib (Odomzo Ò ), an oral smoothened (SMO) antagonist, is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who present recurrence following surgery or radiation therapy, or those who are not candidates for surgery or radiotherapy. Several studies and randomized controlled trials have been conducted to evaluate the efficacy, safety, and tolerability of this new molecule that has demonstrated a good response rate (44%). Grade 1-2 adverse events have also been repor-ted. Further studies of real-world experiences are needed to better understand the correct management of the drug, alternative dosing regimens, and differences with other hedgehog inhibitors. This article provides a complete overview of the pharmacology and pharmacokinetics of sonidegib and a report of the trials and studies conducted. The most frequent adverse events and their correct management are also discussed.

show abstract

Section: Perspectives and Conclusionmentioning

confidence: 99%

Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma

Villani

Fabbrocini

Costa

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Vismodegib is the first FDA-approved SMO inhibitor [13], in 2012, for the treatment of basal cell carcinoma and has been subsequently studied against colon [14], pancreatic [15], and medulloblasto-ma tumors [16]. In patients suffering from resistance to treatment [17][18][19][20], sonidegib, the second inhibitor of SMO approved by the FDA in 2015 [21], is used [22][23][24]. Other possible inhibitors against SMO, subjected to research, and possibly used in resistance to vismodegib and sonidegib [25], are natural products such as chalcone 12 [26], analogs of vitamin D3 [27], or itraconazole, the new inhibitor that might act against mutated SMO [28].…”

Section: Resultsmentioning

confidence: 99%

Inhibition of the Sonic Hedgehog Pathway by Cyclopamine or GLI1 siRNA Reduces In Vivo Tumorigenesis of Human Medulloblastoma Cells Xenotransplanted to Immunodeficient Nude Mice

Rosa¹,

Sánchez²,

Enguita-Germán³

et al. 2019

Advances Transl Med Res

View full text Add to dashboard Cite

Medulloblastoma is an aggressive tumor; grade IV of the WHO classification that develops in the cerebellum, mostly linked to infancy and adolescence. It can be classified histologically and molecularly in different subtypes. Morphologically it can be divided into classical, desmoplastic/nodular, anaplastic, and large cell medulloblastoma. Molecularly, there are four groups: Wnt, Shh (sonic hedgehog), group 3 (mainly linked to MYC amplification), and group 4 (for unclassified tumors). Our work tries to prove the inhibition of the Shh pathway in two medulloblastoma cell lines: DAOY, a desmoplastic cerebellar medulloblastoma cell line of the Shh molecular group; and D283 Med, derived from a metastasis to peritoneum, possibly corresponding to an aggressive group 3 medulloblastoma. Cyclopamine, an inhibitor of the SMO oncogenic protein, and GLI1 siRNA were used as inhibitory agents of the Shh pathway in the two cell lines. For the in vivo assay, for each cell line, each experimental group consisted of 6 mice injected subcutaneously with control cells on the right flank, and cells treated with cyclopamine or GLI1 siRNA on the left flank. In the cell lines studied, cyclopamine showed a high inhibitory growth of subcutaneous tumors in the D283 Med and DAOY lines. The siRNA treatment, however, was only effective in the D283 Med cell line.

show abstract

“…The coronavirus disease (COVID‐19) outbreak caused by an infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) poses several challenges to treatment decisions and management of oncologic patients with advanced skin cancers 1 . Sonidegib, an orally dosed smoothened (SMO) antagonist, is approved for the treatment of adult patients with locally advanced basal cell carcinomas (laBCCs) that are not candidates for surgery or radiotherapy 2‐4 …”

Section: Figurementioning

confidence: 99%

“…ment of adult patients with locally advanced basal cell carcinomas (laBCCs) that are not candidates for surgery or radiotherapy. [2][3][4] Herein we present a case of an 80-year-old woman with laBCCs the patient was already very satisfied with the treatment efficacy, and she requested to be put on the approved every other day dose.…”

mentioning

confidence: 99%